Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Decrease in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 137,594 shares, a decrease of 72.1% from the June 15th total of 493,245 shares. Based on an average daily volume of 239,554 shares, the short-interest ratio is currently 0.6 days. Currently, 0.2% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on INDP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. Wall Street Zen raised Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Hedge Funds Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is owned by hedge funds and other institutional investors.

Indaptus Therapeutics Stock Performance

NASDAQ:INDP remained flat at $2.63 during trading hours on Monday. 40,237 shares of the company’s stock traded hands, compared to its average volume of 515,148. The company has a market capitalization of $297.83 million, a P/E ratio of -0.17 and a beta of 1.11. The firm has a fifty day simple moving average of $2.53 and a 200 day simple moving average of $2.38. Indaptus Therapeutics has a one year low of $0.92 and a one year high of $12.77.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Friday, May 15th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.